Syndax Pharmaceuticals (SNDX) Scheduled to Post Quarterly Earnings on Monday

Share on StockTwits

Syndax Pharmaceuticals (NASDAQ:SNDX) is set to issue its quarterly earnings data after the market closes on Monday, November 5th. Analysts expect the company to announce earnings of ($0.76) per share for the quarter.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its earnings results on Tuesday, August 7th. The company reported ($0.74) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.13. Syndax Pharmaceuticals had a negative return on equity of 80.35% and a negative net margin of 3,190.51%. The firm had revenue of $0.38 million for the quarter, compared to the consensus estimate of $0.38 million. On average, analysts expect Syndax Pharmaceuticals to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Shares of NASDAQ SNDX traded up $0.31 during midday trading on Tuesday, reaching $4.92. The company’s stock had a trading volume of 20,431 shares, compared to its average volume of 430,916. Syndax Pharmaceuticals has a 12-month low of $4.36 and a 12-month high of $15.20. The company has a market capitalization of $117.01 million, a PE ratio of -1.63 and a beta of 1.27.

An institutional investor recently raised its position in Syndax Pharmaceuticals stock. Bank of New York Mellon Corp lifted its holdings in Syndax Pharmaceuticals Inc (NASDAQ:SNDX) by 72.9% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 80,372 shares of the company’s stock after buying an additional 33,892 shares during the period. Bank of New York Mellon Corp owned approximately 0.34% of Syndax Pharmaceuticals worth $564,000 at the end of the most recent reporting period. Institutional investors own 64.29% of the company’s stock.

A number of equities analysts have recently weighed in on the company. ValuEngine upgraded Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, July 6th. HC Wainwright assumed coverage on Syndax Pharmaceuticals in a research note on Thursday, July 12th. They issued a “buy” rating and a $30.00 target price on the stock. Zacks Investment Research downgraded Syndax Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, October 10th. Citigroup cut their target price on Syndax Pharmaceuticals from $15.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday, October 11th. Finally, Morgan Stanley downgraded Syndax Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $6.00 target price on the stock. in a research note on Monday. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $18.20.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial.

See Also: Beta

Earnings History for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply